COVID-19 has caused enormous disruption in the life sciences industry, putting many clinical studies on hold while accelerating others. Hundreds of studies that were halted or put on hold due to the COVID-19 pandemic will now require careful re-starting as sponsors look to re-initiate their clinical trials.
The rapid push for new treatments and vaccines and the re-initiation of halted studies is creating an urgent need for better process, collaboration, and connectivity across the design and execution of study protocols and amendments. Studies must accommodate and account for disruptions in patient availability and access to study sites and clinics.
Appian helps researchers adapt
Appian's Study Design and Execution Life Cycle (SDEL) solution addresses these challenges and more. It's a centralized resource that enables end-to-end visibility across all your clinical studies, from study design through execution.
With Appian SDEL, your organizations can:
Appian SDEL helps ensure that your processes are up to date, key stakeholders have clear communications between each other, and operations are audit-ready should that occur. What's more, you'll establish a solid process for capturing decisions, so you can change protocols easily and ultimately accelerate the entire design process.
Empowering efficiency, safety, and compliance
Appian's automation helps you work more efficiently. With Appian's low-code automation platform, you'll be able to automate the initiation, kickoff, and coordination of your study design and execution, including the assignment of roles and tasks and follow-up sessions with stakeholders. Who are your key stakeholders? What external data sources will they need for decision-making? Appian's automation facilitates answers to these questions and more.
SDEL in action
Through automation, heightened visibility and transparency, Appian's SDEL helps large multinational life sciences firms navigate these details and accelerate the design, initiation, and planning phase. This involved:
The overall solution extends the process into planning involving other stakeholders, getting budgeting information, and reviewing and finalizing initial site list suggestions. In additional phases, Appian's SDEL will facilitate the management and orchestration of protocol amendments.
Want to know more about the power of low-code automation for updating and managing treatment protocols in a rapidly changing environment? I'll share more use cases where Appian has helped life sciences organizations, plus tips on ramping up studies quickly while maintaining patient safety and regulatory requirements, in my Appian World 2020 virtual session Wednesday, May 13, at 12:00 PM EDT. If you haven't yet, sign up for Appian World 2020 today!
Appian is the unified platform for change. We accelerate customers’ businesses by discovering, designing, and automating their most important processes. The Appian Low-Code Platform combines the key capabilities needed to get work done faster, Process Mining + Workflow + Automation, in a unified low-code platform. Appian is open, enterprise-grade and trusted by industry leaders.